|
WO2020223583A1
|
|
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
|
TW202043487A
|
|
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
|
TW202102218A
|
|
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2020190604A1
|
|
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
WO2020180663A1
|
|
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2020132437A1
|
|
Therapies for squamous cell carcinomas
|
|
WO2020092720A2
|
|
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2020069027A1
|
|
Treatment of hematological malignancies with inhibitors of menin
|
|
TW202023556A
|
|
Treatment of adenocarcinomas with mapk pathway inhibitors
|
|
BR112020023559A2
|
|
method for preparing a desired tipifarnib enantiomer and method for transforming an enantiomerically enriched amine
|
|
WO2019113269A1
|
|
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
US2020216471A1
|
|
Substituted inhibitors of menin-mll and methods of use
|
|
AR112823A1
|
|
MENINA-MLL SUBSTITUTE INHIBITORS, AND METHODS OF USE
|
|
AU2018313738A1
|
|
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2018226976A1
|
|
Methods and compositions for inhibiting the interaction of menin with mll proteins
|
|
WO2018175746A1
|
|
Methods for treating hematological malignancies and ewing's sarcoma
|
|
EP3542800A1
|
|
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2018106818A1
|
|
Methods of promoting beta cell proliferation
|
|
WO2018106820A1
|
|
Methods of promoting beta cell proliferation
|
|
US2018235952A1
|
|
Methods of treating cancer with farnesyltransferase inhibitors
|
